Phase one of the institute's trial tested the drugs VS-6766 and everolimus in 30 patients with a range of KRAS mutations, including those with advanced lung, ovarian and thyroid cancer. In a previous trial ...
from Google Alert - health https://ift.tt/n5Tstco
via IFTTT
0 comments:
Post a Comment